EXCEED THE SPACE PROVIDED. Our hypothesis for aim 1 is that unresponsiveness to a non-tolerant [3-cell autoantigen is lost, if it is presented by antigen resenting cells in the pancreatic draining lymph node. This can occur, even if only lower numbers of autoaggressive T cells with reduced avidity are present. The ensuing autoimmune process develops slowly and also contains a (counter)-regulatory component in addition to the aggressive driver clones directed to the non-tolerant antigen. We hypothesize that this regulatory response is directed to other islet antigens and is capable of controlling the autoaggressive response. This notion will be tested in a novel model of spontaneous autoimmune diabetes, where tolerance to a [3-cell antigen is lost without external triggers or addition of T cell receptor transgenic autoaggressive lymphocytes. We postulate that this is one of the most physiological autoimmune models developed to date. The hypothesis to be evaluated in aim 2 is that the initiating autoantigen needs to be expressed throughout the autoimmune process in order to maintain activated autoaggressive driver T-cells. Conversely, the addition of a non-tolerant autoantigen late into an already established autoimmune process will only marginally accelerate the disease course, since a sufficient number of 'driver clones' seeing other autoantigens has already been established. These studies will use a tetracycline-dependent promoter system and directly address the pathogenetic importance of antigenic spreading in autoimmunity. We believe that these two goals will greatly improve our understanding of how antigens are driving an autoaggressive process and will clarify the central role antigen presenting cells and regulatory lymphocytes play in breaking or maintaining unresponsiveness. Our approach is carefully designed to avoid the creation of experimentally artificial non-physiological conditions in order to provide in vivo scenarios that are as close as possible to the situations that we find in human individuals. Thus, no T cell receptor transgenic models or viral triggers as they have been established previously in RIP-LCMV models will be utilized to address our hypotheses. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI044451-06
Application #
6837120
Study Section
Immunological Sciences Study Section (IMS)
Program Officer
Ridge, John P
Project Start
1998-09-30
Project End
2007-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
6
Fiscal Year
2005
Total Cost
$277,500
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Bresson, Damien; Fousteri, Georgia; Manenkova, Yulia et al. (2011) Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. J Autoimmun 37:342-51
Van Belle, Tom L; Juntti, Therese; Liao, Jeanette et al. (2010) Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment. J Autoimmun 34:445-52
Filippi, Christophe M; Juedes, Amy E; Oldham, Janine E et al. (2008) Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes 57:2684-92
Bresson, D; von Herrath, M (2007) Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev 6:315-22
Martinic, Marianne M; Juedes, Amy E; Bresson, Damien et al. (2007) Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice. Diabetes 56:1059-68
Burrer, Renaud; Buchmeier, Michael J; Wolfe, Tom et al. (2007) Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies. Am J Pathol 170:557-66
Barral, Ana Maria; Thomas, Helen E; Ling, Eleanor M et al. (2006) SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J Autoimmun 27:166-73
Burrer, Renaud; von Herrath, Matthias G; Wolfe, Tom et al. (2006) Autoantibodies exacerbate the severity of MHV-induced encephalitis. Adv Exp Med Biol 581:399-402
Christen, Urs; von Herrath, Matthias G (2005) Infections and autoimmunity--good or bad? J Immunol 174:7481-6
Rhode, Antje; Pauza, Mary E; Barral, Ana Maria et al. (2005) Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 175:3516-24

Showing the most recent 10 out of 33 publications